Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

20%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (7)
P 2 (1)
P 3 (2)
P 4 (2)

Trial Status

Not Yet Recruiting7
Recruiting7
Completed4
Terminated1
Unknown1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT06947876RecruitingPrimary

PUFFINS Brain Health Study

NCT07541651Not Yet Recruiting

Study on Eye-Brain Cross-Organ Mapping and Systemic Disease Association Based on Multimodal Big Data

NCT07531797Not ApplicableCompletedPrimary

Effect of High Frequency Cerebellar Repetitive Transcranial Magnetic Stimulation on Functional Ambulation of Patients With Cerebral Small Vessel Disease

NCT07317557Not ApplicableNot Yet RecruitingPrimary

Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease

NCT05356104Phase 2RecruitingPrimary

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

NCT07372937Not Yet RecruitingPrimary

Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease

NCT07068620Not ApplicableRecruitingPrimary

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys

NCT07370844Not ApplicableNot Yet RecruitingPrimary

VR Training to Improve Postoperative Cognitive Function in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery

NCT06674460Phase 3RecruitingPrimary

Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

NCT07180472Phase 4Not Yet RecruitingPrimary

Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol

NCT07128212Not ApplicableCompleted

Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1

NCT07093515Not Yet RecruitingPrimary

Biomarkers, Risk Assessment, Imaging, and Neurodegeneration in Cerebral Small Vessel Disease (BRAIN-CSVD)

NCT05715710RecruitingPrimary

Correlation Between Deep Medullary Veins and Cognitive Dysfunction in Cerebral Small Vessel Disease

NCT06667635Not Yet RecruitingPrimary

Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging:A Multi-center Study

NCT06643013Not ApplicableRecruitingPrimary

Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease

NCT05374005RecruitingPrimary

The Impact of Excessive Dietary Sodium on Brain Health

NCT02169739Not ApplicableTerminated

Remote Preconditioning Over Time To Empower Cerebral Tissue

NCT01932203Phase 4UnknownPrimary

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

NCT02033291Completed

Blood-brain Barrier Quantification in Cerebral Small Vessel Disease

NCT01658306Phase 3CompletedPrimary

Clinical Trial on Remote Ischemic Preconditioning and Cerebral Small Vessel Disease

Showing all 20 trials

Research Network

Activity Timeline